CCCC Stock Overview
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases.
C4 Therapeutics, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$7.93|
|52 Week High||US$38.05|
|52 Week Low||US$4.84|
|1 Month Change||-16.88%|
|3 Month Change||-25.82%|
|1 Year Change||-78.36%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-68.89%|
Recent News & Updates
Earnings Release: Here's Why Analysts Cut Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Price Target To US$29.00May 10
Industry Analysts Just Upgraded Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Revenue Forecasts By 62%Jun 02
Read This Before Selling C4 Therapeutics, Inc. (NASDAQ:CCCC) SharesMar 15
What You Need To Know About C4 Therapeutics, Inc.'s (NASDAQ:CCCC) Investor CompositionFeb 08
|CCCC||US Biotechs||US Market|
Return vs Industry: CCCC underperformed the US Biotechs industry which returned -14.4% over the past year.
Return vs Market: CCCC underperformed the US Market which returned -18.5% over the past year.
|CCCC Average Weekly Movement||12.3%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: CCCC is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: CCCC's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers.
C4 Therapeutics, Inc. Fundamentals Summary
|CCCC fundamental statistics|
Is CCCC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CCCC income statement (TTM)|
|Cost of Revenue||US$87.14m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.18|
|Net Profit Margin||-220.71%|
How did CCCC perform over the long term?See historical performance and comparison